Case ReportOpen Access

PD-1/PD-L1 Checkpoint in Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Case Report

Volume 3 - Issue 2

**Antonella Bianchi¹*, Simona Ferrari¹, Gabriella Gullotta¹, Antonella Grasso² and Ombretta Annibali³**

Author Information Open or Close
- ¹Unit of Pathology, University Hospital Campus Bio-Medico, Italy
- ²Breast Care Unit, University Hospital Campus Bio-Medico, Italy
- ³Unit of Hematology, Stem Cell Transplantation, University Hospital Campus Bio-Medico, Italy
*Corresponding author: Antonella Bianchi, Unit of Pathology, University Hospital Campus Bio-Medico, Via Alvaro del Portillo, 200, Rome, Italy

Received: March 05, 2018; Published: March 16, 2018

DOI: 10.26717/BJSTR.2018.03.000865

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Breast implant-associated anaplastic large cell lymphoma (BI-ALCL) is a rare form of malignancy that arises around mammary implants in patients undergoing prosthetic surgery. It has been included as a provisional entity in the revised WHO classification of lymphoid malignancy. The PD-1/PD-L1 axis is one of the major mechanisms of immune escaping exerted by several cancer types in which up-regulation of PD-L1 is observed. We report the presence of PD-1/PD-L1 checkpoint in a case of BI-ALCL of a 67 year old woman, whom previously had undergone mastectomy and reconstruction for breast carcinoma.

Keywords: PD-1/PD-L1; BI-ALCL; Lymphomas; Lymphoprolipherative Diseases

Abbreviations: PD-1: Programmed Death-1; PD-L1: Programmed Death-Ligand 1; BI-ALCL: Breast Implant-Associated Anaplastic Large Cell Lymphoma; ALK: Anaplastic Lymphoma Kinase; TCR: T-Cell Receptor; CHL: Classical Hodgkin’s Lymphoma; PTCL: Peripheral T-cell Lymphoma; FFPE: Fixed Formalin Paraffin Embedded